Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks ...

(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") ...

Tuesday, the agency signed off on SpringWorks’ Gomekli (mirdametinib) as a treatment for the rare genetic disorder ...

The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...

Merck KGaA is in advanced negotiations to acquire U.S. biotech firm SpringWorks Therapeutics. While a deal isn't finalized, SpringWorks' share value surged following the talks. This acquisition could ...

Recent health news highlights include Gilead's upbeat 2025 forecast, Edwards Lifesciences surpassing profit estimates, New ...

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority review on a key drug and Third Harmonic restructured.

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

BofA analyst Alec Stranahan raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $65 from $55 and keeps a Buy rating on the ...

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, sales continue to soar for Lilly and Novo Nordisk’s GLP-1s and Regeneron ...

Toyota Motor Corp is recalling 106,061 U.S. vehicles over a brake fluid leak that can reduce braking ability and increase the ...

Merck KGaA, the German healthcare and technology conglomerate, has announced that it is in advanced negotiations to acquire ...